Drug therapies for treatment of idiopathic pulmonary fibrosis: a systematic review, Bayesian network meta-analysis, and cost-effectiveness analysisResearch in context

Drug therapies for treatment of idiopathic pulmonary fibrosis: a systematic review, Bayesian network meta-analysis, and cost-effectiveness analysisResearch in context

Summary: Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis and a high economic burden for individuals and healthcare resources. Studies of the costs associated with the efficiency of IPF medications are scarce. We aimed to conduct a netwo...

Full description

Bibliographic Details
Main Authors:	Chunyang Zhao, Yan Yin, Chengrui Zhu, Min Zhu, Tianlong Ji, Zhonghao Li, Jiayi Cai
Format:	Article
Language:	English
Published:	Elsevier 2023-07-01
Series:	EClinicalMedicine
Subjects:	Idiopathic pulmonary fibrosis Drug strategy Bayesian network meta-analysis Cost-effectiveness analysis All-cause mortality Acute exacerbation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537023002481

Similar Items

Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis
by: Miia Kärkkäinen, et al.
Published: (2018-05-01)

The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
by: Hiroyuki Kamiya, et al.
Published: (2020-03-01)

Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis
by: Keisuke Anan, et al.
Published: (2022-10-01)

Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis
by: Esam H Alhamad, et al.
Published: (2020-01-01)

Exacerbation of idiopathic pulmonary fibrosis
by: S. N. Avdeev, et al.
Published: (2020-03-01)

Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
by: Elisabetta Balestro, et al.
Published: (2019-10-01)

Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis
by: Margaret Neighbors, et al.
Published: (2023-06-01)

Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
by: Kodai Kawamura, et al.
Published: (2017-06-01)

Idiopathic pulmonary fibrosis and diabetes mellitus: a meta-analysis and systematic review
by: Le Bai, et al.
Published: (2021-06-01)

Molecular and Genetic Biomarkers in Idiopathic Pulmonary Fibrosis: Where Are We Now?
by: Ioannis Tomos, et al.
Published: (2023-10-01)

Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report
by: Kuniaki Hirai, et al.
Published: (2019-01-01)

Neutrophil-to-Lymphocyte Ratio in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
by: Toru Arai, et al.
Published: (2023-11-01)

Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis
by: L. Richeldi
Published: (2012-06-01)

The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
by: Wan-Tong Zhang, et al.
Published: (2021-11-01)

Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)
by: Jean-Marc Naccache, et al.
Published: (2019-04-01)

Successful Rescue of Acute Exacerbation of Idiopathic Pulmonary Fibrosis after Surgery for Lung Cancer: Case Report
by: Chuan HUANG, et al.
Published: (2022-05-01)

Long-term personal air pollution exposure and risk for acute exacerbation of idiopathic pulmonary fibrosis
by: Ioannis Tomos, et al.
Published: (2021-08-01)

Coronavirus disease 2019 vaccination‐induced acute exacerbation in idiopathic pulmonary fibrosis
by: Keishi Sugino, et al.
Published: (2022-11-01)

Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis
by: Tejaswini Kulkarni, et al.
Published: (2024-03-01)

A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials
by: Xiaozheng Wu, et al.
Published: (2024-01-01)

End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation
by: Norimichi Akiyama, et al.
Published: (2022-10-01)

NHLRC2 expression is increased in idiopathic pulmonary fibrosis
by: Mervi Kreus, et al.
Published: (2022-08-01)

Possible Serological Markers to Predict Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
by: Yoshimasa Hachisu, et al.
Published: (2019-05-01)

Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and Their Association with Lung Cancer by Bioinformatics Analysis
by: Juan Manuel Velázquez-Enríquez, et al.
Published: (2023-10-01)

Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
by: Xiu-Li Zhang, et al.
Published: (2023-11-01)

Diverse echocardiographic changes in the course of hypoxia due to acute exacerbation of idiopathic pulmonary fibrosis
by: Toshimitsu Tsugu, et al.
Published: (2020-09-01)

Idiopathic pulmonary fibrosis: current diagnosis and treatment
by: Alexandre Franco Amaral, et al.
Published: (2023-08-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

Acute exacerbation of idiopathic pulmonary fibrosis model in the rats using bleomycin and lipopolysaccharides
by: Sandy Vitria Kurniawan, et al.
Published: (2023-06-01)

Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis
by: Yuko Tanaka, et al.
Published: (2022-06-01)

Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation
by: Alfonso Carleo, et al.
Published: (2020-04-01)

Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone
by: Tang-Hsiu Huang, et al.
Published: (2024-02-01)

Acute exacerbation of postoperative idiopathic pulmonary fibrosis in a patient with lung cancer caused by invasive mechanical ventilation: A case report
by: Bin Qiu, et al.
Published: (2023-11-01)

The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells
by: Benedikt Jäger, et al.
Published: (2021-04-01)

Approach to acute exacerbation of idiopathic pulmonary fibrosis
by: Hammad Bhatti, et al.
Published: (2013-01-01)

Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
by: Mengshu Cao, et al.
Published: (2022-06-01)

C-type lectin Mincle initiates IL-17-mediated inflammation in acute exacerbations of idiopathic pulmonary fibrosis
by: Chen Tao, et al.
Published: (2023-03-01)

Effectiveness and safety of surgical interventions for treating adolescent idiopathic scoliosis: a Bayesian meta-analysis
by: Long Chen, et al.
Published: (2020-07-01)

Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation
by: Sung Woo Moon, et al.
Published: (2019-10-01)

The Role of Serum 1,25-Dihydroxy Vitamin D3 and PCT in Idiopathic Pulmonary Fibrosis
by: Yang L, et al.
Published: (2022-11-01)